Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2021

01-12-2021 | Coronary Heart Disease | Research article

Analysis of prevalence and prognosis of type 2 diabetes mellitus in patients with acute exacerbation of COPD

Authors: Li Lin, Jianxin Shi, Jian Kang, Qiuyue Wang

Published in: BMC Pulmonary Medicine | Issue 1/2021

Login to get access

Abstract

Background

For patients with acute exacerbation of COPD (AECOPD), type 2 diabetes mellitus (T2DM) as comorbidity have poor outcomes. However, data on the impact of previously diagnosed and new- diagnosed T2DM in such a patient population is lacking.

Methods

Inpatients diagnosed with AECOPD in the department of Pulmonary and Critical Care Medicine of The First Hospital of China Medical University during 2011–2017 were enrolled. Data on demography, prevalence of type 2 DM, other comorbidities, hospital stays and laboratory tests (including arterial partial pressure of oxygen [PaO2]) results were recorded. Results were compared with AECOPD patients having previously diagnosed and new-diagnosed type 2 diabetes. Markers associated with development of type 2 DM and the prognosis of AECOPD patients were identified.

Results

Of the 196 patients enrolled in this study, the overall prevalence of T2DM was 26%. The PaO2 in the newly diagnosed T2DM group was considerably lower versus non-diabetic group. The T2DM group had a longer hospital stay and higher troponin level versus the non-diabetic group. AECOPD patients with T2DM were found to be correlated with hypertension. Age, need for assisted ventilation, increased troponin, and elevated fasting blood glucose on admission were risk factors for death in hospitalized AECOPD patients.

Conclusions

AECOPD patients had a higher prevalence of T2DM than the general population; T2DM comorbidity caused lower PaO2, longer hospital stays, and increased troponin. Poor blood glucose control may increase the risk of death in AECOPD patients.
Literature
1.
go back to reference Wang C, Xu J, Yang L, Xu Y, Zhang X, Bai C, Kang J, Ran P, Shen H, Wen F, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet (London, England). 2018;391(10131):1706–17.CrossRef Wang C, Xu J, Yang L, Xu Y, Zhang X, Bai C, Kang J, Ran P, Shen H, Wen F, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): a national cross-sectional study. Lancet (London, England). 2018;391(10131):1706–17.CrossRef
2.
go back to reference Raju S, Brigham EP, Paulin LM, Putcha N, Balasubramanian A, Hansel NN, McCormack MC. The burden of rural COPD: Analyses from the National Health and Nutrition Examination Survey (NHANES). Am J Respir Crit Care Med. 2019;2019:219. Raju S, Brigham EP, Paulin LM, Putcha N, Balasubramanian A, Hansel NN, McCormack MC. The burden of rural COPD: Analyses from the National Health and Nutrition Examination Survey (NHANES). Am J Respir Crit Care Med. 2019;2019:219.
3.
go back to reference Viegi G, Scognamiglio A, Baldacci S, Pistelli F, Carrozzi L. Epidemiology of chronic obstructive pulmonary disease (COPD). Respiration. 2001;68(1):4–19.PubMedCrossRef Viegi G, Scognamiglio A, Baldacci S, Pistelli F, Carrozzi L. Epidemiology of chronic obstructive pulmonary disease (COPD). Respiration. 2001;68(1):4–19.PubMedCrossRef
4.
go back to reference Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–65.PubMedCrossRef Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2013;187(4):347–65.PubMedCrossRef
5.
go back to reference Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957–63.PubMedCrossRef Suissa S, Dell’Aniello S, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012;67(11):957–63.PubMedCrossRef
6.
go back to reference Martinez CH, Han MK. Contribution of the environment and comorbidities to chronic obstructive pulmonary disease phenotypes. Med Clin North Am. 2012;96(4):713–27.PubMedPubMedCentralCrossRef Martinez CH, Han MK. Contribution of the environment and comorbidities to chronic obstructive pulmonary disease phenotypes. Med Clin North Am. 2012;96(4):713–27.PubMedPubMedCentralCrossRef
7.
go back to reference Ho TW, Huang CT, Ruan SY, Tsai YJ, Lai F, Yu CJ. Diabetes mellitus in patients with chronic obstructive pulmonary disease-The impact on mortality. PLoS ONE. 2017;12(4):e0175794.PubMedPubMedCentralCrossRef Ho TW, Huang CT, Ruan SY, Tsai YJ, Lai F, Yu CJ. Diabetes mellitus in patients with chronic obstructive pulmonary disease-The impact on mortality. PLoS ONE. 2017;12(4):e0175794.PubMedPubMedCentralCrossRef
8.
9.
go back to reference Diez-Manglano J, Recio Iglesias J, Varela Aguilar JM, Almagro Mena P, Zubillaga Garmendia G. Effectiveness of a simple intervention on management of acute exacerbations of chronic obstructive pulmonary disease and its cardiovascular comorbidities: COREPOC study. Med Clin (Barc). 2017;149(6):240–7.CrossRef Diez-Manglano J, Recio Iglesias J, Varela Aguilar JM, Almagro Mena P, Zubillaga Garmendia G. Effectiveness of a simple intervention on management of acute exacerbations of chronic obstructive pulmonary disease and its cardiovascular comorbidities: COREPOC study. Med Clin (Barc). 2017;149(6):240–7.CrossRef
10.
go back to reference Parappil A, Depczynski B, Collett P, Marks GB. Effect of comorbid diabetes on length of stay and risk of death in patients admitted with acute exacerbations of COPD. Respirology. 2010;15(6):918–22.PubMedCrossRef Parappil A, Depczynski B, Collett P, Marks GB. Effect of comorbid diabetes on length of stay and risk of death in patients admitted with acute exacerbations of COPD. Respirology. 2010;15(6):918–22.PubMedCrossRef
11.
go back to reference Flattet Y, Garin N, Serratrice J, Perrier A, Stirnemann J, Carballo S. Determining prognosis in acute exacerbation of COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:467–75.PubMedPubMedCentralCrossRef Flattet Y, Garin N, Serratrice J, Perrier A, Stirnemann J, Carballo S. Determining prognosis in acute exacerbation of COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:467–75.PubMedPubMedCentralCrossRef
12.
go back to reference Lee MC, Lee CH, Chien SC, Chang JH, She HL, Wang JY, Yu MC. Inhaled corticosteroids increase the risk of pneumonia in patients with chronic obstructive pulmonary disease: a nationwide cohort study. Medicine (Baltimore). 2015;94(42):e1723.CrossRef Lee MC, Lee CH, Chien SC, Chang JH, She HL, Wang JY, Yu MC. Inhaled corticosteroids increase the risk of pneumonia in patients with chronic obstructive pulmonary disease: a nationwide cohort study. Medicine (Baltimore). 2015;94(42):e1723.CrossRef
13.
go back to reference Rambaran K, Bhagan B, Ali A, Ali F, Toolsie S, Lobin R, Beharry S, Ghany S, Mohammed S, Davis G, et al. High prevalence of diabetes mellitus in a cohort of patients with chronic obstructive pulmonary disease in Trinidad, West Indies. Turk Thorac J. 2019;20(1):12–7.PubMedPubMedCentralCrossRef Rambaran K, Bhagan B, Ali A, Ali F, Toolsie S, Lobin R, Beharry S, Ghany S, Mohammed S, Davis G, et al. High prevalence of diabetes mellitus in a cohort of patients with chronic obstructive pulmonary disease in Trinidad, West Indies. Turk Thorac J. 2019;20(1):12–7.PubMedPubMedCentralCrossRef
14.
go back to reference Koskela HO, Salonen PH, Niskanen L. Hyperglycaemia during exacerbations of asthma and chronic obstructive pulmonary disease. Clin Respir J. 2013;7(4):382–9.PubMedCrossRef Koskela HO, Salonen PH, Niskanen L. Hyperglycaemia during exacerbations of asthma and chronic obstructive pulmonary disease. Clin Respir J. 2013;7(4):382–9.PubMedCrossRef
15.
go back to reference Xu G, Liu B, Sun Y, Du Y, Snetselaar LG, Hu FB, Bao W. Prevalence of diagnosed type 1 and type 2 diabetes among U.S. adults in 2016 and 2017: population based study. BMJ. 2018;362:k1497.PubMedPubMedCentralCrossRef Xu G, Liu B, Sun Y, Du Y, Snetselaar LG, Hu FB, Bao W. Prevalence of diagnosed type 1 and type 2 diabetes among U.S. adults in 2016 and 2017: population based study. BMJ. 2018;362:k1497.PubMedPubMedCentralCrossRef
16.
go back to reference Anjana RM, Deepa M, Pradeepa R, Mahanta J, Narain K, Das HK, Adhikari P, Rao PV, Saboo B, Kumar A, et al. Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR-INDIAB population-based cross-sectional study. Lancet Diabetes Endocrinol. 2017;5(8):585–96.PubMedCrossRef Anjana RM, Deepa M, Pradeepa R, Mahanta J, Narain K, Das HK, Adhikari P, Rao PV, Saboo B, Kumar A, et al. Prevalence of diabetes and prediabetes in 15 states of India: results from the ICMR-INDIAB population-based cross-sectional study. Lancet Diabetes Endocrinol. 2017;5(8):585–96.PubMedCrossRef
17.
go back to reference Koskela HO, Salonen PH, Romppanen J, Niskanen L. A history of diabetes but not hyperglycaemia during exacerbation of obstructive lung disease has impact on long-term mortality: a prospective, observational cohort study. BMJ Open. 2015;5(1):e006794.PubMedPubMedCentralCrossRef Koskela HO, Salonen PH, Romppanen J, Niskanen L. A history of diabetes but not hyperglycaemia during exacerbation of obstructive lung disease has impact on long-term mortality: a prospective, observational cohort study. BMJ Open. 2015;5(1):e006794.PubMedPubMedCentralCrossRef
18.
go back to reference Baker EH, Janaway CH, Philips BJ, Brennan AL, Baines DL, Wood DM, Jones PW. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax. 2006;61(4):284–9.PubMedPubMedCentralCrossRef Baker EH, Janaway CH, Philips BJ, Brennan AL, Baines DL, Wood DM, Jones PW. Hyperglycaemia is associated with poor outcomes in patients admitted to hospital with acute exacerbations of chronic obstructive pulmonary disease. Thorax. 2006;61(4):284–9.PubMedPubMedCentralCrossRef
19.
go back to reference Lin CS, Liu CC, Yeh CC, Chang YC, Chung CL, Lane HL, Shih CC, Chen TL, Liao CC. Diabetes risks and outcomes in chronic obstructive pulmonary disease patients: two nationwide population-based retrospective cohort studies. PLoS ONE. 2017;12(8):e0181815.PubMedPubMedCentralCrossRef Lin CS, Liu CC, Yeh CC, Chang YC, Chung CL, Lane HL, Shih CC, Chen TL, Liao CC. Diabetes risks and outcomes in chronic obstructive pulmonary disease patients: two nationwide population-based retrospective cohort studies. PLoS ONE. 2017;12(8):e0181815.PubMedPubMedCentralCrossRef
20.
go back to reference Rubinsztajn R, Przybylowski T, Grabicki M, Karwat K, Maskey-Warzechowska M, Batura-Gabryel H, Chazan R. Comorbidities in chronic obstructive pulmonary disease: results of a national multicenter research project. Adv Clin Exp Med. 2019;28(3):319–24.PubMedCrossRef Rubinsztajn R, Przybylowski T, Grabicki M, Karwat K, Maskey-Warzechowska M, Batura-Gabryel H, Chazan R. Comorbidities in chronic obstructive pulmonary disease: results of a national multicenter research project. Adv Clin Exp Med. 2019;28(3):319–24.PubMedCrossRef
21.
go back to reference Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000;117(5 Suppl 2):398s–401s.PubMedCrossRef Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest. 2000;117(5 Suppl 2):398s–401s.PubMedCrossRef
22.
go back to reference Parappil A, Depczynski B, Collett P, Marks GB. Effect of comorbid diabetes on length of stay and risk of death in patients admitted with acute exacerbations of COPD. Respirology (Carlton, Vic). 2010;15(6):918–22.CrossRef Parappil A, Depczynski B, Collett P, Marks GB. Effect of comorbid diabetes on length of stay and risk of death in patients admitted with acute exacerbations of COPD. Respirology (Carlton, Vic). 2010;15(6):918–22.CrossRef
23.
go back to reference Flattet Y, Garin N, Serratrice J, Perrier A, Stirnemann J, Carballo S. Determining prognosis in acute exacerbation of COPD. Int J Chronic Obstr Pulmonary Dis. 2017;12:467–75.CrossRef Flattet Y, Garin N, Serratrice J, Perrier A, Stirnemann J, Carballo S. Determining prognosis in acute exacerbation of COPD. Int J Chronic Obstr Pulmonary Dis. 2017;12:467–75.CrossRef
24.
go back to reference Rambaran K, Bhagan B, Ali A, Ali F, Toolsie S, Lobin R, Beharry S, Ghany S, Mohammed S, Davis G, et al. High prevalence of diabetes mellitus in a cohort of patients with chronic obstructive pulmonary disease in Trinidad, West Indies. Turk Thor J. 2019;20(1):12–7.CrossRef Rambaran K, Bhagan B, Ali A, Ali F, Toolsie S, Lobin R, Beharry S, Ghany S, Mohammed S, Davis G, et al. High prevalence of diabetes mellitus in a cohort of patients with chronic obstructive pulmonary disease in Trinidad, West Indies. Turk Thor J. 2019;20(1):12–7.CrossRef
25.
go back to reference Hsu IL, Lu C-L, Li C-C, Tsai S-H, Chen C-Z, Hu SC, Li C-Y. Population-based cohort study suggesting a significantly increased risk of developing chronic obstructive pulmonary disease in people with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2018;138:66–74.PubMedCrossRef Hsu IL, Lu C-L, Li C-C, Tsai S-H, Chen C-Z, Hu SC, Li C-Y. Population-based cohort study suggesting a significantly increased risk of developing chronic obstructive pulmonary disease in people with type 2 diabetes mellitus. Diabetes Res Clin Pract. 2018;138:66–74.PubMedCrossRef
26.
go back to reference Gläser S, Krüger S, Merkel M, Bramlage P, Herth FJF. Chronic obstructive pulmonary disease and diabetes mellitus: a systematic review of the literature. Respir Int Rev Thorac Dis. 2015;89(3):253–64. Gläser S, Krüger S, Merkel M, Bramlage P, Herth FJF. Chronic obstructive pulmonary disease and diabetes mellitus: a systematic review of the literature. Respir Int Rev Thorac Dis. 2015;89(3):253–64.
27.
go back to reference Winther JA, Brynildsen J, Høiseth AD, Følling I, Brekke PH, Christensen G, Hagve T-A, Verbalis JG, Omland T, Røsjø H. Prevalence and prognostic significance of hyponatremia in patients with acute exacerbation of chronic obstructive pulmonary disease: data from the akershus cardiac examination (ACE) 2 study. PLoS ONE. 2016;11(8):e0161232–e0161232.PubMedPubMedCentralCrossRef Winther JA, Brynildsen J, Høiseth AD, Følling I, Brekke PH, Christensen G, Hagve T-A, Verbalis JG, Omland T, Røsjø H. Prevalence and prognostic significance of hyponatremia in patients with acute exacerbation of chronic obstructive pulmonary disease: data from the akershus cardiac examination (ACE) 2 study. PLoS ONE. 2016;11(8):e0161232–e0161232.PubMedPubMedCentralCrossRef
28.
go back to reference Hitchings AW, Lai D, Jones PW, Baker EH. Metformin in severe exacerbations of chronic obstructive pulmonary disease: a randomised controlled trial. Thorax. 2016;71(7):587–93.PubMedCrossRef Hitchings AW, Lai D, Jones PW, Baker EH. Metformin in severe exacerbations of chronic obstructive pulmonary disease: a randomised controlled trial. Thorax. 2016;71(7):587–93.PubMedCrossRef
29.
go back to reference Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123(11):1001–6.PubMedCrossRef Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123(11):1001–6.PubMedCrossRef
30.
go back to reference Caughey GE, Preiss AK, Vitry AI, Gilbert AL, Roughead EE. Comorbid diabetes and COPD: impact of corticosteroid use on diabetes complications. Diabetes Care. 2013;36(10):3009–14.PubMedPubMedCentralCrossRef Caughey GE, Preiss AK, Vitry AI, Gilbert AL, Roughead EE. Comorbid diabetes and COPD: impact of corticosteroid use on diabetes complications. Diabetes Care. 2013;36(10):3009–14.PubMedPubMedCentralCrossRef
31.
go back to reference Ceviker Y, Sayiner A. Comparison of two systemic steroid regimens for the treatment of COPD exacerbations. Pulm Pharmacol Ther. 2014;27(2):179–83.PubMedCrossRef Ceviker Y, Sayiner A. Comparison of two systemic steroid regimens for the treatment of COPD exacerbations. Pulm Pharmacol Ther. 2014;27(2):179–83.PubMedCrossRef
32.
go back to reference Rogliani P, Calzetta L, Segreti A, Barrile A, Cazzola M. Diabetes mellitus among outpatients with COPD attending a university hospital. Acta Diabetol. 2014;51(6):933–40.PubMedCrossRef Rogliani P, Calzetta L, Segreti A, Barrile A, Cazzola M. Diabetes mellitus among outpatients with COPD attending a university hospital. Acta Diabetol. 2014;51(6):933–40.PubMedCrossRef
33.
go back to reference Yang CJ, Liao WI, Tang ZC, Wang JC, Lee CH, Chang WC, Hsu CW, Tang SE, Tsai SH. Glycated hemoglobin A1c-based adjusted glycemic variables in patients with diabetes presenting with acute exacerbation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2017;12:1923–32.PubMedPubMedCentralCrossRef Yang CJ, Liao WI, Tang ZC, Wang JC, Lee CH, Chang WC, Hsu CW, Tang SE, Tsai SH. Glycated hemoglobin A1c-based adjusted glycemic variables in patients with diabetes presenting with acute exacerbation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2017;12:1923–32.PubMedPubMedCentralCrossRef
34.
go back to reference Louis M. Punjabi NM (2009) Effects of acute intermittent hypoxia on glucose metabolism in awake healthy volunteers. J Appl Physiol. 1985;106(5):1538–44.CrossRef Louis M. Punjabi NM (2009) Effects of acute intermittent hypoxia on glucose metabolism in awake healthy volunteers. J Appl Physiol. 1985;106(5):1538–44.CrossRef
35.
go back to reference Oltmanns KM, Gehring H, Rudolf S, Schultes B, Rook S, Schweiger U, Born J, Fehm HL, Peters A. Hypoxia causes glucose intolerance in humans. Am J Respir Crit Care Med. 2004;169(11):1231–7.PubMedCrossRef Oltmanns KM, Gehring H, Rudolf S, Schultes B, Rook S, Schweiger U, Born J, Fehm HL, Peters A. Hypoxia causes glucose intolerance in humans. Am J Respir Crit Care Med. 2004;169(11):1231–7.PubMedCrossRef
36.
go back to reference Adrogue HJ, Chap Z, Okuda Y, Michael L, Hartley C, Entman M, Field JB. Acidosis-induced glucose intolerance is not prevented by adrenergic blockade. Am J Physiol. 1988;255(6 Pt 1):E812-823.PubMed Adrogue HJ, Chap Z, Okuda Y, Michael L, Hartley C, Entman M, Field JB. Acidosis-induced glucose intolerance is not prevented by adrenergic blockade. Am J Physiol. 1988;255(6 Pt 1):E812-823.PubMed
37.
go back to reference Oguntibeju O. Type 2 diabetes mellitus, oxidative stress and inflammation: examining the links. Int J Physiol Pathophysiol Pharmacol. 2019;11(3):45–63.PubMedPubMedCentral Oguntibeju O. Type 2 diabetes mellitus, oxidative stress and inflammation: examining the links. Int J Physiol Pathophysiol Pharmacol. 2019;11(3):45–63.PubMedPubMedCentral
38.
go back to reference Kinney GL, Black-Shinn JL, Wan ES, Make B, Regan E, Lutz S, Soler X, Silverman EK, Crapo J, Hokanson JE. Pulmonary function reduction in diabetes with and without chronic obstructive pulmonary disease. Diabetes Care. 2014;37(2):389–95.PubMedPubMedCentralCrossRef Kinney GL, Black-Shinn JL, Wan ES, Make B, Regan E, Lutz S, Soler X, Silverman EK, Crapo J, Hokanson JE. Pulmonary function reduction in diabetes with and without chronic obstructive pulmonary disease. Diabetes Care. 2014;37(2):389–95.PubMedPubMedCentralCrossRef
39.
go back to reference Davis WA, Knuiman M, Kendall P, Grange V, Davis TM. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care. 2004;27(3):752–7.PubMedCrossRef Davis WA, Knuiman M, Kendall P, Grange V, Davis TM. Glycemic exposure is associated with reduced pulmonary function in type 2 diabetes: the Fremantle Diabetes Study. Diabetes Care. 2004;27(3):752–7.PubMedCrossRef
40.
go back to reference Lim SY, Rhee EJ, Sung KC. Metabolic syndrome, insulin resistance and systemic inflammation as risk factors for reduced lung function in Korean nonsmoking males. J Korean Med Sci. 2010;25(10):1480–6.PubMedPubMedCentralCrossRef Lim SY, Rhee EJ, Sung KC. Metabolic syndrome, insulin resistance and systemic inflammation as risk factors for reduced lung function in Korean nonsmoking males. J Korean Med Sci. 2010;25(10):1480–6.PubMedPubMedCentralCrossRef
41.
go back to reference Lawlor DA, Ebrahim S, Smith GD. Associations of measures of lung function with insulin resistance and Type 2 diabetes: findings from the British Women’s Heart and Health Study. Diabetologia. 2004;47(2):195–203.PubMedCrossRef Lawlor DA, Ebrahim S, Smith GD. Associations of measures of lung function with insulin resistance and Type 2 diabetes: findings from the British Women’s Heart and Health Study. Diabetologia. 2004;47(2):195–203.PubMedCrossRef
43.
go back to reference Kasirye Y, Simpson M, Mamillapalli CK, Epperla N, Liang H, Yale SH. Association between blood glucose level and outcomes in patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease. WMJ. 2013;112(6):244–9.PubMed Kasirye Y, Simpson M, Mamillapalli CK, Epperla N, Liang H, Yale SH. Association between blood glucose level and outcomes in patients hospitalized for acute exacerbation of chronic obstructive pulmonary disease. WMJ. 2013;112(6):244–9.PubMed
44.
go back to reference Kolahian S, Leiss V, Nürnberg B. Diabetic lung disease: fact or fiction? Rev Endocrine Metabolic Disord. 2019;20(3):303–19.CrossRef Kolahian S, Leiss V, Nürnberg B. Diabetic lung disease: fact or fiction? Rev Endocrine Metabolic Disord. 2019;20(3):303–19.CrossRef
45.
go back to reference Hofford JM, Milakofsky L, Vogel WH, Sacher RS, Savage GJ, Pell S. The nutritional status in advanced emphysema associated with chronic bronchitis. A study of amino acid and catecholamine levels. Am Rev Respir Dis. 1990;141(4 Pt 1):902–8.PubMedCrossRef Hofford JM, Milakofsky L, Vogel WH, Sacher RS, Savage GJ, Pell S. The nutritional status in advanced emphysema associated with chronic bronchitis. A study of amino acid and catecholamine levels. Am Rev Respir Dis. 1990;141(4 Pt 1):902–8.PubMedCrossRef
46.
go back to reference Baillard C, Boussarsar M, Fosse JP, Girou E, Le Toumelin P, Cracco C, Jaber S, Cohen Y, Brochard L. Cardiac troponin I in patients with severe exacerbation of chronic obstructive pulmonary disease. Intensive Care Med. 2003;29(4):584–9.PubMedCrossRef Baillard C, Boussarsar M, Fosse JP, Girou E, Le Toumelin P, Cracco C, Jaber S, Cohen Y, Brochard L. Cardiac troponin I in patients with severe exacerbation of chronic obstructive pulmonary disease. Intensive Care Med. 2003;29(4):584–9.PubMedCrossRef
47.
go back to reference Janata KM, Leitner JM, Holzer-Richling N, Janata A, Laggner AN, Jilma B. Troponin T predicts in-hospital and 1-year mortality in patients with pulmonary embolism. Eur Respir J. 2009;34(6):1357–63.PubMedCrossRef Janata KM, Leitner JM, Holzer-Richling N, Janata A, Laggner AN, Jilma B. Troponin T predicts in-hospital and 1-year mortality in patients with pulmonary embolism. Eur Respir J. 2009;34(6):1357–63.PubMedCrossRef
48.
go back to reference Parker D, Liu J, Roberts M, Eaton C. Is inflammatory chronic obstructive pulmonary disease a coronary heart disease risk equivalent? A longitudinal analysis of the third National Health and Nutrition Examination Survey (NHANES III), 1988–1994. BMC Pulmonary Med. 2014;14:195.CrossRef Parker D, Liu J, Roberts M, Eaton C. Is inflammatory chronic obstructive pulmonary disease a coronary heart disease risk equivalent? A longitudinal analysis of the third National Health and Nutrition Examination Survey (NHANES III), 1988–1994. BMC Pulmonary Med. 2014;14:195.CrossRef
49.
go back to reference Brekke PH, Omland T, Holmedal SH, Smith P, Soyseth V. Determinants of cardiac troponin T elevation in COPD exacerbation - a cross-sectional study. BMC Pulm Med. 2009;9:35.PubMedPubMedCentralCrossRef Brekke PH, Omland T, Holmedal SH, Smith P, Soyseth V. Determinants of cardiac troponin T elevation in COPD exacerbation - a cross-sectional study. BMC Pulm Med. 2009;9:35.PubMedPubMedCentralCrossRef
Metadata
Title
Analysis of prevalence and prognosis of type 2 diabetes mellitus in patients with acute exacerbation of COPD
Authors
Li Lin
Jianxin Shi
Jian Kang
Qiuyue Wang
Publication date
01-12-2021
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2021
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-020-01371-9

Other articles of this Issue 1/2021

BMC Pulmonary Medicine 1/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.